
Matthew Hickman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2329466/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Practitioner and digitally delivered interventions for reducing hazardous and harmful alcohol consumption in people not seeking alcohol treatment: a systematic review and network metaâ€analysis. Addiction, 2023, 118, 17-29.	3.3	2
2	Impact of new consent procedures on uptake of the schools-based human papillomavirus (HPV) vaccination programme. Journal of Public Health, 2022, 44, 199-206.	1.8	6
3	Acceptability of, and barriers and facilitators to, a pilot physical health service for people who inject drugs: A qualitative study with service users and providers. International Journal of Drug Policy, 2022, 99, 103437.	3.3	1
4	Cohort Profile: The Melbourne Injecting Drug User Cohort Study (SuperMIX). International Journal of Epidemiology, 2022, 51, e123-e130.	1.9	14
5	Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. Journal of Hepatology, 2022, 76, 549-557.	3.7	24
6	Role of peer support in a hepatitis C elimination programme. Journal of Viral Hepatitis, 2022, 29, 43-51.	2.0	8
7	Prenatal stress and offspring depression in adulthood: The mediating role of childhood trauma. Journal of Affective Disorders, 2022, 297, 45-52.	4.1	9
8	Modeling the populationâ€level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia. Addiction, 2022, 117, 1338-1352.	3.3	11
9	The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study. Lancet Public Health, The, 2022, 7, e136-e145.	10.0	14
10	Causes of death among people who used illicit opioids in England, 2001–18: a matched cohort study. Lancet Public Health, The, 2022, 7, e126-e135.	10.0	25
11	Self-harm and suicide during and after opioid agonist treatment among primary care patients in England: a cohort study. Lancet Psychiatry,the, 2022, 9, 151-159.	7.4	6
12	Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO. The Lancet Gastroenterology and Hepatology, 2022, 7, 353-366.	8.1	10
13	The effectiveness of low dead space syringes for reducing the risk of hepatitis C virus acquisition among people who inject drugs - findings from a national survey in England, Wales, and Northern Ireland. Clinical Infectious Diseases, 2022, , .	5.8	0
14	An ecological study of temporal trends in †deaths of despair' in England and Wales. Social Psychiatry and Psychiatric Epidemiology, 2022, 57, 1135-1144.	3.1	8
15	Overdose prevention centres in the UK. Lancet Public Health, The, 2022, 7, e196-e197.	10.0	10
16	The effectiveness of psychosocial interventions at reducing the frequency of alcohol and drug use in parents: findings of a Cochrane Review and metaâ€analyses. Addiction, 2022, 117, 2571-2582.	3.3	6
17	Risk clustering and psychopathology from a multi-center cohort of Indian children, adolescents, and young adults. Development and Psychopathology, 2022, , 1-9.	2.3	1
18	Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2022, 7, 426-445.	8.1	50

#	Article	IF	CITATIONS
19	Realâ€world outcomes of rapid regional hepatitis C virus treatment scaleâ€up among people who inject drugs in Tayside, Scotland. Alimentary Pharmacology and Therapeutics, 2022, 55, 568-579.	3.7	12
20	Nucleation increases the visual appeal of lager but does not alter overall likeability or drinking rate. Harm Reduction Journal, 2022, 19, 39.	3.2	0
21	The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001–2018: Findings from the OATS retrospective linkage study. Drug and Alcohol Dependence, 2022, 236, 109464.	3.2	7
22	Development of a multicomponent intervention to increase parental vaccine confidence and young people's access to the universal HPV vaccination programme in England: protocol for a co-design study. BMJ Open, 2022, 12, e062050.	1.9	2
23	Development of an educational package for the universal human papillomavirus (HPV) vaccination programme: a co-production study with young people and key informants. Research Involvement and Engagement, 2022, 8, 16.	2.9	2
24	Exploration of attitudes regarding uptake of COVID-19 vaccines among vaccine hesitant adults in the UK: a qualitative analysis. BMC Infectious Diseases, 2022, 22, 407.	2.9	13
25	The impact of opioid agonist treatment on hospitalisations for injecting-related diseases among an opioid dependent population: A retrospective data linkage study. Drug and Alcohol Dependence, 2022, 236, 109494.	3.2	12
26	Individual-, family- and school-based interventions to prevent multiple risk behaviours relating to alcohol, tobacco and drug use in young people aged 8-25 years: a systematic review and meta-analysis. BMC Public Health, 2022, 22, .	2.9	3
27	Changes in the development of opioid tolerance on re-exposure among people who use heroin: A qualitative study. PLoS ONE, 2022, 17, e0269379.	2.5	1
28	Mortality in the SuperMIX cohort of people who inject drugs in Melbourne, Australia: a prospective observational study. Addiction, 2022, 117, 3091-3098.	3.3	4
29	Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis. BMC Gastroenterology, 2022, 22, .	2.0	1
30	Parent and child coâ€resident status among an Australian communityâ€based sample of methamphetamine smokers. Drug and Alcohol Review, 2021, 40, 1275-1280.	2.1	5
31	A prospective cohort of people who use methamphetamine in Melbourne and nonâ€metropolitan Victoria, Australia: Baseline characteristics and correlates of methamphetamine dependence. Drug and Alcohol Review, 2021, 40, 1239-1248.	2.1	13
32	Alcohol use and cognitive functioning in young adults: improving causal inference. Addiction, 2021, 116, 292-302.	3.3	12
33	Polygenic contributions to alcohol use and alcohol use disorders across population-based and clinically ascertained samples. Psychological Medicine, 2021, 51, 1147-1156.	4.5	18
34	Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia. International Journal of Epidemiology, 2021, 49, 1774-1775.	1.9	10
35	Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and metaâ€analysis. Addiction, 2021, 116, 1664-1676.	3.3	9
36	Opioid overdose risk during and after drug treatment for heroin dependence: An incidence density case–control study nested in the <scp>VEdeTTE</scp> cohort. Drug and Alcohol Review, 2021, 40, 281-286.	2.1	4

#	Article	IF	CITATIONS
37	Evaluating the effectiveness of the smartphone app, Drink Less, compared with the NHS alcohol advice webpage, for the reduction of alcohol consumption among hazardous and harmful adult drinkers in the UK at 6â€month followâ€up: protocol for a randomised controlled trial. Addiction, 2021, 116, 412-425.	3.3	22
38	Mental health before and during the COVID-19 pandemic in two longitudinal UK population cohorts. British Journal of Psychiatry, 2021, 218, 334-343.	2.8	330
39	Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001–2018: Findings from the OATS retrospective cohort study. Drug and Alcohol Dependence, 2021, 218, 108354.	3.2	5
40	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. Journal of Hepatology, 2021, 74, 20-30.	3.7	77
41	Testing the validity of national drug surveys: comparison between a general population cohort and household surveys. Addiction, 2021, 116, 2076-2083.	3.3	2
42	Conceptualising natural and quasi experiments in public health. BMC Medical Research Methodology, 2021, 21, 32.	3.1	61
43	Psychosocial Interventions to Improve Psychological, Social and Physical Wellbeing in Family Members Affected by an Adult Relative's Substance Use: A Systematic Search and Review of the Evidence. International Journal of Environmental Research and Public Health, 2021, 18, 1793.	2.6	18
44	Understanding adolescent health risk behaviour and socioeconomic position: A grounded theory study of UK young adults. Sociology of Health and Illness, 2021, 43, 528-544.	2.1	4
45	Effectiveness of psychosocial interventions for reducing parental substance misuse. The Cochrane Library, 2021, 2021, CD012823.	2.8	12
46	The Influence of Alcohol Consumption on Fighting, Shoplifting and Vandalism in Young Adults. International Journal of Environmental Research and Public Health, 2021, 18, 3509.	2.6	3
47	The costâ€effectiveness of caseâ€finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK. Journal of Viral Hepatitis, 2021, 28, 897-908.	2.0	3
48	Testing the association between tobacco and cannabis use and cognitive functioning: Findings from an observational and Mendelian randomization study. Drug and Alcohol Dependence, 2021, 221, 108591.	3.2	6
49	Public health information on COVID-19 for international travellers: lessons learned from a mixed-method evaluation. Public Health, 2021, 193, 116-123.	2.9	6
50	Young adult cancer risk behaviours originate in adolescence: a longitudinal analysis using ALSPAC, a UK birth cohort study. BMC Cancer, 2021, 21, 365.	2.6	2
51	Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. Lancet Psychiatry,the, 2021, 8, 301-309.	7.4	20
52	Association between self-reported signs and symptoms and SARS-CoV-2 antibody detection in UK key workers. Journal of Infection, 2021, 82, 151-161.	3.3	7
53	Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Public Health, The, 2021, 6, e309-e323.	10.0	99
54	The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15â€year retrospective cohort study. Addiction, 2021, 116, 3139-3152.	3.3	14

#	Article	IF	CITATIONS
55	Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scaleâ€up of directâ€acting antiâ€viral therapy in community drug services: realâ€world data. Addiction, 2021, 116, 2893-2907.	3.3	28
56	The effect of needle and syringe program and opioid agonist therapy on the risk of HIV, hepatitis B and C virus infection for people who inject drugs in Amsterdam, the Netherlands: findings from an emulated target trial. Addiction, 2021, 116, 3115-3126.	3.3	15
57	Accuracy of four lateral flow immunoassays for anti SARS-CoV-2 antibodies: a head-to-head comparative study. EBioMedicine, 2021, 68, 103414.	6.1	17
58	Refining the content and design of an alcohol reduction app, Drink Less, to improve its usability and effectiveness: a mixed methods approach. F1000Research, 2021, 10, 511.	1.6	6
59	Incidence of <i>Clostridioides difficile</i> infection (CDI) related to antibiotic prescribing by GP surgeries in Wales. Journal of Antimicrobial Chemotherapy, 2021, 76, 2437-2445.	3.0	4
60	Big data and predictive modelling for the opioid crisis: existing research and future potential. The Lancet Digital Health, 2021, 3, e397-e407.	12.3	21
61	Inflammation and Depression: A Public Health Perspective. Brain, Behavior, and Immunity, 2021, 95, 1-3.	4.1	25
62	The impact of directâ€acting antivirals on hepatitis C viraemia among people who inject drugs in England; realâ€world data 2011–2018. Journal of Viral Hepatitis, 2021, 28, 1452-1463.	2.0	10
63	Overlapping Key Populations and HIV Transmission in Tijuana, Mexico: A Modelling Analysis of Epidemic Drivers. AIDS and Behavior, 2021, 25, 3814-3827.	2.7	7
64	Secondary analyses to test the impact on inequalities and uptake of the schools-based human papillomavirus (HPV) vaccination programme by stage of implementation of a new consent policy in the south-west of England. BMJ Open, 2021, 11, e044980.	1.9	8
65	The Melbourne Safe Injecting Room Attracted People Most in Need of Its Service. American Journal of Preventive Medicine, 2021, 61, 217-224.	3.0	14
66	Mapping drug epidemiology futures. International Journal of Drug Policy, 2021, 94, 103378.	3.3	4
67	Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection. International Journal of Drug Policy, 2021, 96, 103419.	3.3	2
68	High COVID-19 transmission potential associated with re-opening universities can be mitigated with layered interventions. Nature Communications, 2021, 12, 5017.	12.8	43
69	Assessing HIV and overdose risks for people who use drugs exposed to compulsory drug abstinence programs (CDAP): A systematic review and meta-analysis. International Journal of Drug Policy, 2021, 96, 103401.	3.3	5
70	Promoting addiction science after Brexit—what can Addiction and SSA do and what does UK government need to do?. Addiction, 2021, 116, 2597-2599.	3.3	0
71	Framing public health response to the opioid and overdose crisis: are there alternatives to cascade of care model?. European Journal of Public Health, 2021, 31, 670-671.	0.3	Ο
72	Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence. JAMA Psychiatry, 2021, 78, 979.	11.0	244

#	Article	IF	CITATIONS
73	Is adolescent multiple risk behaviour associated with reduced socioeconomic status in young adulthood and do those with low socioeconomic backgrounds experience greater negative impact? Findings from two UK birth cohort studies. BMC Public Health, 2021, 21, 1614.	2.9	3
74	P39â€Evaluations of public health interventions using natural experiment evaluation designs and the †̃target trial' framework. , 2021, , .		0
75	Cognitive style and drinking to cope: A prospective cohort study. Addiction, 2021, , .	3.3	1
76	Association of maternal pre-pregnancy BMI and breastfeeding with NAFLD in young adults: a parental negative control study. Lancet Regional Health - Europe, The, 2021, 10, 100206.	5.6	11
77	Experiences of the coronavirus disease-19 (COVID-19) pandemic from the perspectives of young people: Rapid qualitative study. Public Health in Practice, 2021, 2, 100162.	1.5	13
78	Living Under Coronavirus and Injecting Drugs in Bristol (LUCID-B): A qualitative study of experiences of COVID-19 among people who inject drugs. International Journal of Drug Policy, 2021, 98, 103391.	3.3	38
79	Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2021, 73, e107-e118.	5.8	39
80	Evaluating the power of the causal impact method in observational studies of HCV treatment as prevention. Statistical Communications in Infectious Diseases, 2021, 13, .	0.2	1
81	Influence of commissioned provider type and deprivation score on uptake of the childhood flu immunization. Journal of Public Health, 2020, 42, 618-624.	1.8	3
82	Prevention of suicide and reduction of self-harm among people with substance use disorder: A systematic review and meta-analysis of randomised controlled trials. Comprehensive Psychiatry, 2020, 96, 152135.	3.1	25
83	A comparison of trends in wastewaterâ€based data and traditional epidemiological indicators of stimulant consumption in three locations. Addiction, 2020, 115, 462-472.	3.3	13
84	Better data, better policy and better lives: a call for improved drug monitoring and concerted responses. Addiction, 2020, 115, 199-200.	3.3	3
85	Data linkage to monitor hepatitis Câ€associated endâ€stage liver disease and hepatocellular carcinoma inpatient stays in England. Journal of Viral Hepatitis, 2020, 27, 20-27.	2.0	2
86	Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluation. Addiction, 2020, 115, 702-713.	3.3	8
87	Opioid use disorder. Nature Reviews Disease Primers, 2020, 6, 3.	30.5	278
88	Consortium on Vulnerability to Externalizing Disorders and Addictions (cVEDA): A developmental cohort study protocol. BMC Psychiatry, 2020, 20, 2.	2.6	27
89	Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. The Lancet Global Health, 2020, 8, e244-e253.	6.3	16
90	Scaling up screening and treatment for elimination of hepatitis C among men who have sex with men in the era of HIV pre-exposure prophylaxis. EClinicalMedicine, 2020, 19, 100217.	7.1	13

#	Article	IF	CITATIONS
91	All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids. JAMA Psychiatry, 2020, 77, 493.	11.0	83
92	Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis. The Lancet Global Health, 2020, 8, e76-e91.	6.3	19
93	Depression, post-traumatic stress disorder, suicidality and self-harm among people who inject drugs: A systematic review and meta-analysis. Drug and Alcohol Dependence, 2020, 207, 107793.	3.2	44
94	Externalising pathways to alcoholâ€related problems in emerging adulthood. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2020, 61, 721-731.	5.2	7
95	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology, 2020, 72, 643-657.	3.7	103
96	Frequency of injecting among people who inject drugs: A systematic review and meta-analysis. International Journal of Drug Policy, 2020, 76, 102619.	3.3	21
97	Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis. International Journal of Drug Policy, 2020, 84, 102866.	3.3	17
98	State anxiety and alcohol choice: Evidence from experimental and online observational studies. Journal of Psychopharmacology, 2020, 34, 1237-1249.	4.0	6
99	Acceptability of a primary care-based opioid and pain review service: a mixed-methods evaluation in England. British Journal of General Practice, 2020, 70, e120-e129.	1.4	7
100	Alcohol consumption and internalising disorders in young adults of ALSPAC: a population-based study. Journal of Epidemiology and Community Health, 2020, 74, jech-2020-213922.	3.7	8
101	Treatment interventions to maintain abstinence from alcohol in primary care: systematic review and network meta-analysis. BMJ, The, 2020, 371, m3934.	6.0	38
102	Evaluation of a primary care-based opioid and pain review service: a mixed-methods evaluation in two GP practices in England. British Journal of General Practice, 2020, 70, e111-e119.	1.4	12
103	Assessing the contribution of alcoholâ€specific causes to socioâ€economic inequalities in mortality in England and Wales 2001–16. Addiction, 2020, 115, 2268-2279.	3.3	14
104	Response to Commentary on Hancock et al . (2020): Low dead space syringes are just one component of an integrated package of care needed to tackle HCV and social exclusion among people who inject drugs. Addiction, 2020, 115, 2407-2408.	3.3	0
105	Life expectancy of people who are dependent on opioids: A cohort study in New South Wales, Australia. Journal of Psychiatric Research, 2020, 130, 435-440.	3.1	15
106	Risk of discharge against medical advice among hospital inpatients with a history of opioid agonist therapy in New South Wales, Australia: A cohort study and nested crossover-cohort analysis. Drug and Alcohol Dependence, 2020, 217, 108343.	3.2	5
107	Co-production of an educational package for the universal human papillomavirus (HPV) vaccination programme tailored for schools with low uptake: a participatory study protocol. BMJ Open, 2020, 10, e039029.	1.9	8
108	Generational trends in US opioid-overdose deaths. Nature Medicine, 2020, 26, 651-652.	30.7	8

#	Article	IF	CITATIONS
109	A Bayesian multivariate factor analysis model for evaluating an intervention by using observational time series data on multiple outcomes. Journal of the Royal Statistical Society Series A: Statistics in Society, 2020, 183, 1437-1459.	1.1	10
110	Assessing the public health effects of cannabis use: can legalization improve the evidence base?. World Psychiatry, 2020, 19, 197-198.	10.4	1
111	Estimating the prevalence of problem drug use from drugâ€related mortality data. Addiction, 2020, 115, 2393-2404.	3.3	20
112	Multiple risk behaviour in adolescence is associated with substantial adverse health and social outcomes in early adulthood: Findings from a prospective birth cohort study. Preventive Medicine, 2020, 138, 106157.	3.4	23
113	Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care. BMJ, The, 2020, 368, m322.	6.0	14
114	Association of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence. JAMA Psychiatry, 2020, 77, 1044.	11.0	100
115	The Consortium on Vulnerability to Externalizing Disorders and Addictions (c-VEDA): an accelerated longitudinal cohort of children and adolescents in India. Molecular Psychiatry, 2020, 25, 1618-1630.	7.9	19
116	Mitigating and learning from the impact of COVIDâ€19 infection on addictive disorders. Addiction, 2020, 115, 1007-1010.	3.3	204
117	Adolescent multiple risk behaviours cluster by number of risks rather than distinct risk profiles in the ALSPAC cohort. BMC Public Health, 2020, 20, 290.	2.9	12
118	Increasing uptake of hepatitis C virus infection case-finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial. British Journal of General Practice, 2020, 70, e581-e588.	1.4	8
119	Patients without records and records without patients: review of patient records in primary care and implications for surveillance of antibiotic prescribing in rural China. BMC Health Services Research, 2020, 20, 564.	2.2	5
120	Prisons can also improve drug user health in the community. Addiction, 2020, 115, 914-915.	3.3	0
121	Containment and care? A qualitative interview study exploring police custody staff views about delivering brief alcohol interventions to heavy drinking arrestees. Drugs: Education, Prevention and Policy, 2020, 27, 436-444.	1.3	1
122	Evaluating the causal impact of individual alcohol licensing decisions on local health and crime using natural experiments with synthetic controls. Addiction, 2020, 115, 2021-2031.	3.3	23
123	Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis. The Lancet Clobal Health, 2020, 8, e440-e450.	6.3	25
124	Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review. Drug and Alcohol Dependence, 2020, 209, 107899.	3.2	3
125	Reweighting national survey data for small area behaviour estimates: modelling alcohol consumption in Local Authorities in England. Population Health Metrics, 2020, 18, 1.	2.7	20
126	Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study. The Lancet Gastroenterology and Hepatology, 2020, 5, 295-305.	8.1	114

#	Article	IF	CITATIONS
127	Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence. International Journal of Drug Policy, 2020, 77, 102656.	3.3	20
128	Costâ€effectiveness of the HepCATT intervention in specialist drug clinics to improve caseâ€finding and engagement with HCV treatment for people who inject drugs in England. Addiction, 2020, 115, 1509-1521.	3.3	8
129	Global opioid agonist treatment: a review of clinical practices by country. Addiction, 2020, 115, 2243-2254.	3.3	50
130	Qualitative exploration of the intersection between social influences and cultural norms in relation to the development of alcohol use behaviour during adolescence. BMJ Open, 2020, 10, e030556.	1.9	12
131	Healthcare use by people who use illicit opioids (HUPIO): development of a cohort based on electronic primary care records in England. Wellcome Open Research, 2020, 5, 282.	1.8	4
132	Accuracy of UK Rapid Test Consortium (UK-RTC) "AbC-19 Rapid Test―for detection of previous SARS-CoV-2 infection in key workers: test accuracy study. BMJ, The, 2020, 371, m4262.	6.0	42
133	Qualitative Evaluation of Web-Based Digital Intervention to Prevent and Reduce Excessive Alcohol Use and Harm Among Young People Aged 14-15 Years: A "Think-Aloud―Study. JMIR Pediatrics and Parenting, 2020, 3, e19749.	1.6	2
134	Healthcare use by people who use illicit opioids (HUPIO): development of a cohort based on electronic primary care records in England. Wellcome Open Research, 2020, 5, 282.	1.8	10
135	Global, regional, and countryâ€level estimates of hepatitis C infection among people who have recently injected drugs. Addiction, 2019, 114, 150-166.	3.3	178
136	Modelling the potential prevention benefits of a treatâ€all hepatitis C treatment strategy at global, regional and country levels: A modelling study. Journal of Viral Hepatitis, 2019, 26, 1388-1403.	2.0	11
137	The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis. International Journal of Drug Policy, 2019, 73, 172-184.	3.3	67
138	Cannabis use and the risk of tuberculosis: a systematic review. BMC Public Health, 2019, 19, 1006.	2.9	5
139	Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluation. BMJ Open, 2019, 9, e030183.	1.9	9
140	Mapping the hepatitis C cascade of care in people attending drug treatment services in England: A data linkage study. International Journal of Drug Policy, 2019, 72, 55-60.	3.3	4
141	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol). BMJ Open, 2019, 9, e029538.	1.9	30
142	The Independent and Cumulative Effects of Sibling and Peer Bullying in Childhood on Depression, Anxiety, Suicidal Ideation, and Self-Harm in Adulthood. Frontiers in Psychiatry, 2019, 10, 651.	2.6	44
143	Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet, The, 2019, 394, 1560-1579.	13.7	404
144	Strategies to reduce drug-related harm: responding to the evidence base. Lancet, The, 2019, 394, 1490-1493.	13.7	15

#	Article	IF	CITATIONS
145	Alcohol use in late adolescence and early adulthood: The role of generalized anxiety disorder and drinking to cope motives. Drug and Alcohol Dependence, 2019, 204, 107480.	3.2	9
146	Childhood Behavioural Problems and Adverse Outcomes in Early Adulthood: a Comparison of Brazilian and British Birth Cohorts. Journal of Developmental and Life-Course Criminology, 2019, 5, 517-535.	1.2	19
147	Rising opioid-related deaths in England and Scotland must be recognised as a public health crisis. Lancet Psychiatry,the, 2019, 6, 639-640.	7.4	39
148	THU-191-The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK. Journal of Hepatology, 2019, 70, e246-e247.	3.7	0
149	Longâ€Chain ω â€3 Levels Are Associated With Increased Alcohol Sensitivity in a Populationâ€Based Sample of Adolescents. Alcoholism: Clinical and Experimental Research, 2019, 43, 2620-2626.	2.4	3
150	Acceptability and potential impact of delivering sexual health promotion information through social media and dating apps to MSM in England: a qualitative study. BMC Public Health, 2019, 19, 1236.	2.9	24
151	The relative importance of perceived substance misuse use by different peers on smoking, alcohol and illicit drug use in adolescence. Drug and Alcohol Dependence, 2019, 204, 107464.	3.2	4
152	Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England. Value in Health, 2019, 22, 1248-1256.	0.3	12
153	THU-436-The cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the National Health Service health check programme for 40 to 74 year olds in England. Journal of Hepatology, 2019, 70, e349.	3.7	0
154	Barriers and enablers to adolescent self-consent for vaccination: A mixed-methods evidence synthesis. Vaccine, 2019, 37, 417-429.	3.8	16
155	Monitoring the hepatitis C epidemic in England and evaluating intervention scaleâ€up using routinely collected data. Journal of Viral Hepatitis, 2019, 26, 541-551.	2.0	34
156	The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virusâ€infected people who inject drugs in England. Addiction, 2019, 114, 1113-1122.	3.3	33
157	Evaluating the costâ€effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs. Addiction, 2019, 114, 560-570.	3.3	29
158	The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study. Lancet Public Health, The, 2019, 4, e334-e342.	10.0	29
159	Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS ONE, 2019, 14, e0217964.	2.5	14
160	Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis. International Journal of Drug Policy, 2019, 70, 87-93.	3.3	16
161	Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison. American Journal of Epidemiology, 2019, 188, 1539-1551.	3.4	29
162	GS-08-The prevalence of non-alcoholic fatty liver disease in young adults: An impending public health crisis?. Journal of Hepatology, 2019, 70, e45.	3.7	1

#	Article	IF	CITATIONS
163	The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. The Lancet Gastroenterology and Hepatology, 2019, 4, 435-444.	8.1	145
164	Associations of child and adolescent anxiety with later alcohol use and disorders: a systematic review and metaâ€analysis of prospective cohort studies. Addiction, 2019, 114, 968-982.	3.3	49
165	Forecasting the 2021 local burden of population alcoholâ€related harms using Bayesian structural time–series. Addiction, 2019, 114, 994-1003.	3.3	17
166	A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs—Do Gender-Based Differences Vary by Country-Level Indicators?. Journal of Infectious Diseases, 2019, 220, 78-90.	4.0	29
167	O10.4â€Scaling up HCV screening and treatment for eliminating HCV among MSM in UK in the era of HIV pre-exposure prophylaxis. , 2019, , .		0
168	PTU-001â€Diagnostic accuracy of non-invasive liver fibrosis markers in young adults within the ALSPAC population-based cohort. , 2019, , .		0
169	Pathways to optimising antibiotic use in rural China: identifying key determinants in community and clinical settings, a mixed methods study protocol. BMJ Open, 2019, 9, e027819.	1.9	12
170	Reducing hazardous alcohol consumption: an evidence synthesis. Lancet, The, 2019, 394, S24.	13.7	1
171	Evaluating the impact of individual alcohol licensing decisions on local health and crime: a natural experiment with synthetic controls. Lancet, The, 2019, 394, S35.	13.7	1
172	Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records. PLoS Medicine, 2019, 16, e1002965.	8.4	62
173	The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK. Journal of Antimicrobial Chemotherapy, 2019, 74, v5-v16.	3.0	18
174	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver International, 2019, 39, 20-30.	3.9	88
175	Hepatitis case finding among migrants in primary care. The Lancet Gastroenterology and Hepatology, 2019, 4, 3-4.	8.1	4
176	High response and reâ€infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. Journal of Viral Hepatitis, 2019, 26, 519-528.	2.0	48
177	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2019, 4, 135-184.	8.1	370
178	The effectiveness of diversion programmes for offenders using Class A drugs: a systematic review and meta-analysis. Drugs: Education, Prevention and Policy, 2019, 26, 113-124.	1.3	8
179	Assessing the Causal Effect of Binary Interventions from Observational Panel Data with Few Treated Units. Statistical Science, 2019, 34, .	2.8	23
180	Clonal expansion of community-associated meticillin-resistant Staphylococcus aureus (MRSA) in people who inject drugs (PWID): prevalence, risk factors and molecular epidemiology, Bristol, United Kingdom, 2012 to 2017. Eurosurveillance, 2019, 24, .	7.0	17

#	Article	IF	CITATIONS
181	Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016. Eurosurveillance, 2019, 24, .	7.0	14
182	The impact of opiate substitution treatment on mortality risk in drug addicts: a natural experiment study. Health Services and Delivery Research, 2019, 7, 1-92.	1.4	3
183	Title is missing!. , 2019, 16, e1002965.		0
184	Title is missing!. , 2019, 16, e1002965.		0
185	Title is missing!. , 2019, 16, e1002965.		0
186	Title is missing!. , 2019, 16, e1002965.		0
187	Title is missing!. , 2019, 16, e1002965.		Ο
188	Is smoking heaviness causally associated with alcohol use? A Mendelian randomization study in four European cohorts. International Journal of Epidemiology, 2018, 47, 1098-1105.	1.9	17
189	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. Journal of Hepatology, 2018, 68, 402-411.	3.7	105
190	Impact and acceptability of self-consent procedures for the school-based human papillomavirus vaccine: a mixed-methods study protocol. BMJ Open, 2018, 8, e021321.	1.9	14
191	The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom. Addiction, 2018, 113, 1461-1476.	3.3	83
192	â€~DrinkThink' alcohol screening and brief intervention for young people: a qualitative evaluation of training and implementation. Journal of Public Health, 2018, 40, 381-388.	1.8	2
193	Behavior Change Techniques Used in Digital Behavior Change Interventions to Reduce Excessive Alcohol Consumption: A Meta-regression. Annals of Behavioral Medicine, 2018, 52, 530-543.	2.9	52
194	Motivation to reduce alcohol consumption and subsequent attempts at reduction and changes in consumption in increasing and higherâ€risk drinkers in England: a prospective population survey. Addiction, 2018, 113, 817-827.	3.3	11
195	Alcohol Use in Adolescence and Later Working Memory: Findings From a Large Population-Based Birth Cohort. Alcohol and Alcoholism, 2018, 53, 251-258.	1.6	22
196	Association of Combined Patterns of Tobacco and Cannabis Use in Adolescence With Psychotic Experiences. JAMA Psychiatry, 2018, 75, 240.	11.0	46
197	Low resting heart rate, sensation seeking and the course of antisocial behaviour across adolescence and young adulthood. Psychological Medicine, 2018, 48, 2194-2201.	4.5	15
198	Polygenic Risk Score Prediction of Alcohol Dependence Symptoms Across Populationâ€Based and Clinically Ascertained Samples. Alcoholism: Clinical and Experimental Research, 2018, 42, 520-530.	2.4	25

#	Article	IF	CITATIONS
199	Understanding hepatitis C intervention success—Qualitative findings from the Hep <scp>CATT</scp> study. Journal of Viral Hepatitis, 2018, 25, 762-770.	2.0	23
200	Establishing the cascade of care for hepatitis C in England—benchmarking to monitor impact of direct acting antivirals. Journal of Viral Hepatitis, 2018, 25, 482-490.	2.0	23
201	Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination. International Journal of Epidemiology, 2018, 47, 550-560.	1.9	64
202	A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. Journal of Medicinal Chemistry, 2018, 61, 535-542.	6.4	188
203	Protein Degradation via CRL4 ^{CRBN} Ubiquitin Ligase: Discovery and Structure–Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1. Journal of Medicinal Chemistry, 2018, 61, 492-503.	6.4	58
204	Scalingâ€up HCV prevention and treatment interventions in rural United States—model projections for tackling an increasing epidemic. Addiction, 2018, 113, 173-182.	3.3	71
205	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. The Lancet Gastroenterology and Hepatology, 2018, 3, 125-133.	8.1	128
206	Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and metaâ€analysis. Addiction, 2018, 113, 545-563.	3.3	242
207	Effect of initiating drug treatment on the risk of drug-related poisoning death and acquisitive crime among offending heroin users. International Journal of Drug Policy, 2018, 51, 42-51.	3.3	5
208	Effect of multiple risk behaviours in adolescence on educational attainment at age 16 years: a UK birth cohort study. BMJ Open, 2018, 8, e020182.	1.9	19
209	Adolescent self-consent for vaccinations: protocol for a mixed methods systematic review. BMJ Open, 2018, 8, e021335.	1.9	2
210	Examining subgroup effects by socioeconomic status of public health interventions targeting multiple risk behaviour in adolescence. BMC Public Health, 2018, 18, 1180.	2.9	15
211	Qualitative study of Ebola screening at ports of entry to the UK. BMJ Global Health, 2018, 3, e000788.	4.7	7
212	Metaâ€Analysis of Genetic Influences on Initial Alcohol Sensitivity. Alcoholism: Clinical and Experimental Research, 2018, 42, 2349-2359.	2.4	21
213	Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. BMJ Open, 2018, 8, e025204.	1.9	31
214	Effect of glass shape on the pouring accuracy of liquid volume. PLoS ONE, 2018, 13, e0204562.	2.5	9
215	Alcohol Screening and Brief Intervention in Police Custody Suites: Pilot Cluster Randomised Controlled Trial (AcCePT). Alcohol and Alcoholism, 2018, 53, 548-559.	1.6	12
216	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 1397-1409.	9.1	147

#	Article	IF	CITATIONS
217	Usage of low dead space syringes and association with hepatitis C prevalence amongst people who inject drugs in the UK. Drug and Alcohol Dependence, 2018, 192, 118-124.	3.2	8
218	The effect of parental drinking on alcohol use in young adults: the mediating role of parental monitoring and peer deviance. Addiction, 2018, 113, 2041-2050.	3.3	31
219	Commentary on Lai <i>et al</i> . (2018): Potential and limitations of wastewaterâ€based epidemiology in monitoring substance use. Addiction, 2018, 113, 1137-1138.	3.3	3
220	Modelling the impact of a national scaleâ€up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. Addiction, 2018, 113, 2118-2131.	3.3	15
221	Impact of current and scaledâ€up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings—what is required to achieve the WHO's HCV elimination targets?. Addiction, 2018, 113, 1727-1738.	3.3	30
222	Promoting Alcohol Reduction in Non-Treatment Seeking parents (PAReNTS): a protocol for a pilot feasibility cluster randomised controlled trial of alcohol screening and brief interventions to reduce parental alcohol use disorders in vulnerable families. Pilot and Feasibility Studies, 2018, 4, 111.	1.2	6
223	Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. Lancet HIV,the, 2018, 5, e578-e587.	4.7	29
224	Genomeâ€wide association metaâ€analysis of age at first cannabis use. Addiction, 2018, 113, 2073-2086.	3.3	24
225	The cost-effectiveness of needle and syringe provision in preventing transmission of Hepatitis C virus in people who inject drugs. Journal of Hepatology, 2018, 68, S146-S147.	3.7	1
226	Comparing the prevention gains of different treatment strategies at the global, regional, and country level: a modelling study. Journal of Hepatology, 2018, 68, S179-S180.	3.7	0
227	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction, 2018, 113, 1905-1926.	3.3	685
228	Competing global statistics on prevalence of injecting drug use: why does it matter and what can be done?. Addiction, 2018, 113, 1768-1774.	3.3	11
229	Childhood Risk Factors for Heavy Episodic Alcohol Use and Alcohol Problems in Late Adolescence: A Marginal Structural Model Analysis. Journal of Studies on Alcohol and Drugs, 2018, 79, 370-379.	1.0	14
230	Response to: â€~Synthetic control methodology as a tool for evaluating population-level health interventions' by Bouttell <i>et al</i> . Journal of Epidemiology and Community Health, 2018, 72, 864-864.	3.7	0
231	Individual-, family-, and school-level interventions targeting multiple risk behaviours in young people. The Cochrane Library, 2018, 2018, CD009927.	2.8	67
232	DNA methylation from birth to late adolescence and development of multiple-risk behaviours. Journal of Affective Disorders, 2018, 227, 588-594.	4.1	9
233	Reported Theory Use by Digital Interventions for Hazardous and Harmful Alcohol Consumption, and Association With Effectiveness: Meta-Regression. Journal of Medical Internet Research, 2018, 20, e69.	4.3	35
234	Effect of glass markings on drinking rate in social alcohol drinkers. European Journal of Public Health, 2017, 27, ckw142.	0.3	4

#	Article	IF	CITATIONS
235	A systematic review of injecting-related injury and disease among people who inject drugs. Drug and Alcohol Dependence, 2017, 171, 39-49.	3.2	163
236	Hepatitis C virus prevention and treatment prioritization—ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs. Addiction, 2017, 112, 201-203.	3.3	6
237	Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C. Journal of Hepatology, 2017, 66, 1101-1103.	3.7	14
238	Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. Addiction, 2017, 112, 1408-1418.	3.3	130
239	Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction, 2017, 112, 1302-1314.	3.3	80
240	Risk to heroin users of polydrug use of pregabalin or gabapentin. Addiction, 2017, 112, 1580-1589.	3.3	126
241	Therapeutic interventions for alcohol dependence in non-inpatient settings: a systematic review and network meta-analysis (protocol). Systematic Reviews, 2017, 6, 77.	5.3	9
242	The Rate of Change in Alcohol Misuse Across Adolescence is Heritable. Alcoholism: Clinical and Experimental Research, 2017, 41, 57-64.	2.4	9
243	New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an <i>Addiction</i> series. Addiction, 2017, 112, 1126-1127.	3.3	2
244	Patterns of cannabis use during adolescence and their association with harmful substance use behaviour: findings from a UK birth cohort. Journal of Epidemiology and Community Health, 2017, 71, 764-770.	3.7	70
245	Polygenic Risk, Personality Dimensions, and Adolescent Alcohol Use Problems: A Longitudinal Study. Journal of Studies on Alcohol and Drugs, 2017, 78, 442-451.	1.0	27
246	Impact of opioid substitution therapy on the HIV prevention benefit of antiretroviral therapy for people who inject drugs. Aids, 2017, 31, 1181-1190.	2.2	22
247	Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact. International Journal of Epidemiology, 2017, 46, 1582-1592.	1.9	25
248	Rejoinder to: Implementation of low dead space syringes in response to an outbreak of HIV among people who inject drugs: A response to Kesten et al International Journal of Drug Policy, 2017, 43, 142-143.	3.3	0
249	How to eliminate HCV infection by antiviral treatment. Journal of Hepatology, 2017, 67, 5-6.	3.7	16
250	Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The Lancet Global Health, 2017, 5, e1192-e1207.	6.3	1,020
251	Personalised digital interventions for reducing hazardous and harmful alcohol consumption in community-dwelling populations. The Cochrane Library, 2017, 2017, CD011479.	2.8	192
252	A prospective cohort study of hospital separations among people who inject drugs in Australia: 2008–2013. BMJ Open, 2017, 7, e014854.	1.9	15

#	Article	IF	CITATIONS
253	Insights into the link between drug use and criminality: Lifetime offending of criminally-active opiate users. Drug and Alcohol Dependence, 2017, 179, 309-316.	3.2	40
254	Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. The Cochrane Library, 2017, 2017, CD012021.	2.8	158
255	Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. International Journal of Drug Policy, 2017, 47, 26-33.	3.3	53
256	The intervention effect of local alcohol licensing policies on hospital admission and crime: a natural experiment using a novel Bayesian synthetictime-series method. Journal of Epidemiology and Community Health, 2017, 71, 912-918.	3.7	49
257	Effects of Excessive Alcohol Use on AntisocialÂBehavior Across Adolescence andÂEarly Adulthood. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 857-865.	0.5	23
258	Clobal, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. The Lancet Clobal Health, 2017, 5, e1208-e1220.	6.3	334
259	Assessment of rates of recanting and hair testing as a biological measure of drug use in a general population sample of young people. Addiction, 2017, 112, 477-485.	3.3	21
260	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. International Journal of Drug Policy, 2017, 47, 51-60.	3.3	54
261	Alcohol screening and brief interventions for adults and young people in health and community-based settings: a qualitative systematic literature review. BMC Public Health, 2017, 17, 562.	2.9	38
262	Pathways through opiate use and offending: A systematic review. International Journal of Drug Policy, 2017, 39, 1-13.	3.3	44
263	Acceptability of low dead space syringes and implications for their introduction: A qualitative study in the West of England. International Journal of Drug Policy, 2017, 39, 99-108.	3.3	19
264	Comparison of cannabinoids in hair with selfâ€reported cannabis consumption in heavy, light and nonâ€cannabis users. Drug and Alcohol Review, 2017, 36, 220-226.	2.1	49
265	Among friends: a qualitative exploration of the role of peers in young people's alcohol use using Bourdieu's concepts of habitus, field and capital. Sociology of Health and Illness, 2017, 39, 30-46.	2.1	38
266	Adaptation of the ASSIST peer-led smoking intervention to deliver information from the Talk to FRANK drug education website (ASSIST+FRANK): a pilot cluster-randomised controlled trial. Lancet, The, 2017, 390, S1.	13.7	0
267	Testing the impact of local alcohol licencing policies on reported crime rates in England. Journal of Epidemiology and Community Health, 2017, 71, 137-145.	3.7	39
268	Parental alcohol use and risk of behavioral and emotional problems in offspring. PLoS ONE, 2017, 12, e0178862.	2.5	21
269	Estimating the number of people who inject drugs in Australia. BMC Public Health, 2017, 17, 757.	2.9	38
270	Investigating local policy drivers for alcohol harm prevention: a comparative case study of two local authorities in England. BMC Public Health, 2017, 17, 825.	2.9	8

#	Article	IF	CITATIONS
271	Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling. Public Health Research, 2017, 5, 1-118.	1.3	20
272	Adapting the ASSIST model of informal peer-led intervention delivery to the Talk to FRANK drug prevention programme in UK secondary schools (ASSIST + FRANK): intervention development, refinement and a pilot cluster randomised controlled trial. Public Health Research, 2017, 5, 1-98.	1.3	10
273	Importance and Contribution of Community, Social, and Healthcare Risk Factors for Hepatitis C Infection in Pakistan. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1920-1928.	1.4	22
274	Script in a Day intervention for individuals who are injecting opioids: a feasibility randomized control trial. Journal of Public Health, 2016, 38, fdv161.	1.8	3
275	OP36â€Evaluating youth mentoring for young people at risk of exclusion from secondary school: results from a feasibility randomised control trial study. Journal of Epidemiology and Community Health, 2016, 70, A24.1-A24.	3.7	0
276	Hepatitis C – Assessment to Treatment Trial (HepCATT) in primary care: study protocol for a cluster randomised controlled trial. Trials, 2016, 17, 366.	1.6	13
277	A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation. PLoS ONE, 2016, 11, e0145705.	2.5	6
278	HIV treatment as prevention among people who inject drugs – a re-evaluation of the evidence. International Journal of Epidemiology, 2016, 46, dyw180.	1.9	19
279	Low hepatitis B testing among migrants: a cross-sectional study in a UK city. British Journal of General Practice, 2016, 66, e382-e391.	1.4	22
280	Does exposure to opioid substitution treatment at prison release reduce the risk of death? A prospective, observational study in England. Lancet, The, 2016, 388, S11.	13.7	2
281	Youth mentoring for young people at risk of exclusion from secondary school: a feasibility randomised controlled trial. Lancet, The, 2016, 388, S22.	13.7	1
282	Inferring the intervention effect of local alcohol licensing policies on hospital admission and violent crime: a natural experiment with Bayesian synthetic controls. Lancet, The, 2016, 388, S43.	13.7	4
283	Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium. Translational Psychiatry, 2016, 6, e769-e769.	4.8	136
284	A prospective longitudinal model predicting early adult alcohol problems: evidence for a robust externalizing pathway. Psychological Medicine, 2016, 46, 957-968.	4.5	33
285	Exploratory trial of a school-based alcohol prevention intervention with a family component. Health Education, 2016, 116, 410-431.	0.9	2
286	Not in the vein: â€~missed hits', subcutaneous and intramuscular injections and associated harms among people who inject psychoactive drugs in Bristol, United Kingdom. International Journal of Drug Policy, 2016, 28, 83-90.	3.3	34
287	ls increased hepatitis C virus caseâ€finding combined with current or 8â€week to 12â€week directâ€acting antiviral therapy costâ€effective in UK prisons? A prevention benefit analysis. Hepatology, 2016, 63, 1796-1808.	7.3	58
288	Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Clinical Infectious Diseases, 2016, 62, 1072-1080.	5.8	122

#	Article	IF	CITATIONS
289	Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infectious Diseases, The, 2016, 16, 1385-1398.	9.1	223
290	Impact of treatment for opioid dependence on fatal drugâ€related poisoning: a national cohort study in England. Addiction, 2016, 111, 298-308.	3.3	124
291	Overlapping substance using high-risk groups and infectious diseases: how dynamic modelling can evaluate risk and target HIV prevention. Addiction, 2016, 111, 1512-1515.	3.3	7
292	Moderate alcohol drinking in pregnancy increases risk for children's persistent conduct problems: causal effects in a Mendelian randomisation study. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2016, 57, 575-584.	5.2	45
293	New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. Journal of Viral Hepatitis, 2016, 23, 631-643.	2.0	37
294	Commentary on Cousins et al . (2016): Accumulating evidence on risk of mortality on and off opioid substitution treatment. Addiction, 2016, 111, 83-84.	3.3	1
295	Problem drug use prevalence estimation revisited: heterogeneity in capture–recapture and the role of external evidence. Addiction, 2016, 111, 438-447.	3.3	24
296	Peerâ€led interventions to prevent tobacco, alcohol and/or drug use among young people aged 11–21Âyears: a systematic review and metaâ€analysis. Addiction, 2016, 111, 391-407.	3.3	169
297	Impact of Opioid Substitution Therapy on Antiretroviral Therapy Outcomes: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 2016, 63, 1094-1104.	5.8	174
298	A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. Journal of Viral Hepatitis, 2016, 23, 1009-1016.	2.0	44
299	Local policies to tackle a national problem: Comparative qualitative case studies of an English local authority alcohol availability intervention. Health and Place, 2016, 41, 11-18.	3.3	25
300	Comparison of brief interventions in primary care on smoking and excessive alcohol consumption: a population survey in England. British Journal of General Practice, 2016, 66, e1-e9.	1.4	82
301	Are recent attempts to quit smoking associated with reduced drinking in England? A cross-sectional population survey. BMC Public Health, 2016, 16, 535.	2.9	14
302	Temporal patterns of alcohol consumption and attempts to reduce alcohol intake in England. BMC Public Health, 2016, 16, 917.	2.9	22
303	Uptake of childhood influenza vaccine from 2012–2013 to 2014–2015 in the UK and the implications for high-risk children: a retrospective observational cohort study. BMJ Open, 2016, 6, e010625.	1.9	14
304	Drinking to Cope: a Latent Class Analysis of Coping Motives for Alcohol Use in a Large Cohort of Adolescents. Prevention Science, 2016, 17, 584-594.	2.6	48
305	Propensity score matching for selection of local areas as controls for evaluation of effects of alcohol policies in case series and quasi case–control designs. Public Health, 2016, 132, 40-49.	2.9	9

7.3 0

#	Article	IF	CITATIONS
307	Measurable effects of local alcohol licensing policies on population health in England. Journal of Epidemiology and Community Health, 2016, 70, 231-237.	3.7	52
308	A qualitative investigation of the role of the family in structuring young people's alcohol use. European Journal of Public Health, 2016, 26, 102-110.	0.3	24
309	Barriers and facilitators to uptake of the school-based HPV vaccination programme in an ethnically diverse group of young women. Journal of Public Health, 2016, 38, 569-577.	1.8	49
310	Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. Journal of Hepatology, 2016, 65, 17-25.	3.7	157
311	Connecting the dots, genome-wide association studies in substance use. Molecular Psychiatry, 2016, 21, 733-735.	7.9	31
312	Ethanol Reversal of Tolerance to the Respiratory Depressant Effects of Morphine. Neuropsychopharmacology, 2016, 41, 762-773.	5.4	61
313	Association Between Cannabis and Psychosis: Epidemiologic Evidence. Biological Psychiatry, 2016, 79, 549-556.	1.3	285
314	Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. , 2016, 2016, .		38
315	The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?. PLoS ONE, 2016, 11, e0156213.	2.5	41
316	HCV treatment as prevention in prison: Key issues. Hepatology, 2015, 61, 402-403.	7.3	12
317	Quantifying crime associated with drug use among a large cohort of sanctioned offenders in England and Wales. Drug and Alcohol Dependence, 2015, 155, 52-59.	3.2	30
318	<scp>HCV</scp> treatment rates and sustained viral response among people who inject drugs in seven <scp>UK</scp> sites: real world results and modelling of treatment impact. Journal of Viral Hepatitis, 2015, 22, 399-408.	2.0	86
319	The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and) Tj ETQq1 1	0.784314	rgBT /Over <mark>l</mark> o
320	Mortality in the Melbourne injecting drug user cohort study (MIX). Harm Reduction Journal, 2015, 12, 55.	3.2	21
321	The effect of glass shape on alcohol consumption in a naturalistic setting: a feasibility study. Pilot and Feasibility Studies, 2015, 1, 27.	1.2	10
322	Hepatitis C virus treatment as prevention in people who inject drugs. Current Opinion in Infectious Diseases, 2015, 28, 576-582.	3.1	78
323	Associations of Cannabis and Cigarette Use with Depression and Anxiety at Age 18: Findings from the Avon Longitudinal Study of Parents and Children. PLoS ONE, 2015, 10, e0122896.	2.5	65
324	Healthcare seeking and hospital admissions by people who inject drugs in response to symptoms of injection site infections or injuries in three urban areas of England. Epidemiology and Infection, 2015, 143, 120-131.	2.1	40

#	Article	IF	CITATIONS
325	Hepatitis B infection prevalence by country of birth in migrant populations in a large UK city. Journal of Clinical Virology, 2015, 68, 79-82.	3.1	18
326	The Developmental Relationship Between Depressive Symptoms in Adolescence and Harmful Drinking in Emerging Adulthood: The Role of Peers and Parents. Journal of Youth and Adolescence, 2015, 44, 1752-1766.	3.5	24
327	CC-223, a Potent and Selective Inhibitor of mTOR Kinase: <i>In Vitro</i> and <i>In Vivo</i> Characterization. Molecular Cancer Therapeutics, 2015, 14, 1295-1305.	4.1	48
328	Multiple risk behaviour in adolescence and socio-economic status: findings from a UK birth cohort. European Journal of Public Health, 2015, 25, 44-49.	0.3	83
329	A stepped wedge cluster randomized control trial of dried blood spot testing to improve the uptake of hepatitis C antibody testing within UK prisons. European Journal of Public Health, 2015, 25, 351-357.	0.3	25
330	Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. International Journal of Drug Policy, 2015, , 101669.	3.3	0
331	Cessation of injecting drug use: The effects of health service utilisation, drug use and demographic factors. Drug and Alcohol Dependence, 2015, 154, 208-213.	3.2	16
332	Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vÃa parenteral. International Journal of Drug Policy, 2015, , 101671.	3.3	0
333	The Mediating Role of Deviant Peers on the Link Between Depressed Mood andÂHarmful Drinking. Journal of Adolescent Health, 2015, 56, 153-159.	2.5	22
334	Perinatal and sociodemographic factors at birth predicting conduct problems and violence to age 18Âyears: comparison of Brazilian and British birth cohorts. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2015, 56, 914-922.	5.2	16
335	Mortality among older adults with opioid use disorders in the Veteran's Health Administration, 2000–2011. Drug and Alcohol Dependence, 2015, 147, 32-37.	3.2	52
336	Adolescent cannabis and tobacco use and educational outcomes at age 16: birth cohort study. Addiction, 2015, 110, 658-668.	3.3	80
337	Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223. Journal of Medicinal Chemistry, 2015, 58, 5323-5333.	6.4	29
338	O124 : ls increased HCV case-finding combined with 8 or 12 week interferon-free direct-acting antiviral treatment cost-effective in UK prisons? a cost utility analysis including treatment as prevention benefits. Journal of Hepatology, 2015, 62, S255-S256.	3.7	1
339	Going into the groin: Injection into the femoral vein among people who inject drugs in three urban areas of England. Drug and Alcohol Dependence, 2015, 152, 239-245.	3.2	22
340	Factors affecting repeated cessations of injecting drug use and relapses during the entire injecting career among the Edinburgh Addiction Cohort. Drug and Alcohol Dependence, 2015, 151, 76-83.	3.2	31
341	Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115. Journal of Medicinal Chemistry, 2015, 58, 5599-5608.	6.4	60
342	Cannabis and psychosis. Lancet Psychiatry,the, 2015, 2, 380.	7.4	11

#	Article	IF	CITATIONS
343	Cannabis and psychosis. Lancet Psychiatry,the, 2015, 2, 380-381.	7.4	7
344	Childhood behaviour problems predict crime and violence in late adolescence: Brazilian and British birth cohort studies. Social Psychiatry and Psychiatric Epidemiology, 2015, 50, 579-589.	3.1	40
345	Protocol for a national monthly survey of alcohol use in England with 6-month follow-up: †The Alcohol Toolkit Study'. BMC Public Health, 2015, 15, 230.	2.9	49
346	A pilot feasibility trial of alcohol screening and brief intervention in the police custody setting (ACCEPT): study protocol for a cluster randomised controlled trial. Pilot and Feasibility Studies, 2015, 1, 6.	1.2	4
347	National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005–2009. Drug and Alcohol Dependence, 2015, 146, 17-23.	3.2	76
348	Editorial Commentary:The Impact of Opiate Substitution Therapy and Highly Active Antiretroviral Therapy on Mortality Risk Among People Who Inject Drugs. Clinical Infectious Diseases, 2015, 61, 1166-1168.	5.8	4
349	Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry,the, 2015, 2, 901-908.	7.4	106
350	Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs. International Journal of Drug Policy, 2015, 26, 950-957.	3.3	42
351	Latent Trajectory Classes for Alcoholâ€Related Blackouts from Age 15 to 19 in <scp>ALSPAC</scp> . Alcoholism: Clinical and Experimental Research, 2015, 39, 108-116.	2.4	37
352	The role of <scp>C</scp> ochrane reviews in informing international guidelines: a case study of using the <scp>G</scp> rading of <scp>R</scp> ecommendations, <scp>A</scp> ssessment, <scp>D</scp> evelopment and <scp>E</scp> valuation system to develop World Health Organization guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Addiction, 2015, 110, 891-898.	3.3	147
353	Socioeconomic factors and other sources of variation in the prevalence of genital chlamydia infections: A systematic review and meta-analysis. BMC Public Health, 2015, 15, 729.	2.9	29
354	Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy, 2015, 26, 1028-1038.	3.3	159
355	An appraisal of theoretical approaches to examining behaviours in relation to Human Papillomavirus (HPV) vaccination of young women. Preventive Medicine, 2015, 81, 122-131.	3.4	29
356	Estimating the measurable impact of local alcohol licensing policies on population health in England using ecological longitudinal data. Lancet, The, 2015, 386, S33.	13.7	4
357	Genomic influences on alcohol problems in a population-based sample of young adults. Addiction, 2015, 110, 461-470.	3.3	18
358	What is needed in future drug treatment research? A systematic approach to identify gaps on effectiveness of drug treatment from the EMCDDA. Drugs: Education, Prevention and Policy, 2015, 22, 86-92.	1.3	4
359	The effectiveness and cost-effectiveness of diversion and aftercare programmes for offenders using class A drugs: a systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-168.	2.8	28
360	Preventing alcohol misuse in young people: an exploratory cluster randomised controlled trial of the Kids, Adults Together (KAT) programme. Public Health Research, 2015, 3, 1-188.	1.3	10

#	Article	IF	CITATIONS
361	Prevalence of Chlamydia in Young Adulthood and Association with Life Course Socioeconomic Position: Birth Cohort Study. PLoS ONE, 2014, 9, e104943.	2.5	7
362	Polygenic Scores Predict Alcohol Problems in an Independent Sample and Show Moderation by the Environment. Genes, 2014, 5, 330-346.	2.4	71
363	Authors' reply to Rappuoli and colleagues, Black, and Glennie and colleagues. BMJ, The, 2014, 349, g6758-g6758.	6.0	0
364	Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. International Journal of Epidemiology, 2014, 43, 235-248.	1.9	298
365	Recapture or Precapture? Fallibility of Standard Capture-Recapture Methods in the Presence of Referrals Between Sources. American Journal of Epidemiology, 2014, 179, 1383-1393.	3.4	48
366	Evaluating the role of a galanin enhancer genotype on a range of metabolic, depressive and addictive phenotypes. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 654-664.	1.7	4
367	Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet, The, 2014, 384, 1953-1997.	13.7	492
368	Childhood Internalizing Symptoms Are Negatively Associated with Early Adolescent Alcohol Use. Alcoholism: Clinical and Experimental Research, 2014, 38, 1680-1688.	2.4	31
369	Martin NK et al (Clin Infect Dis 2013; 57[Suppl 2]: S39-45). Clinical Infectious Diseases, 2014, 58, 1203-1203.	5.8	0
370	The association between depressive symptoms from early to late adolescence and later use and harmful use of alcohol. European Child and Adolescent Psychiatry, 2014, 23, 1219-1230.	4.7	58
371	Associations of cannabis and cigarette use with psychotic experiences at age 18: findings from the Avon Longitudinal Study of Parents and Children. Psychological Medicine, 2014, 44, 3435-3444.	4.5	86
372	Examining inequalities in the uptake of the school-based HPV vaccination programme in England: a retrospective cohort study. Journal of Public Health, 2014, 36, 36-45.	1.8	79
373	Strategies to reduce <scp>HCV</scp> disease burden and <scp>HCV</scp> transmission need different models, as what works for endâ€stage liver disease may not work for <scp>HCV</scp> prevalence: a comment on the results presented in <scp>JVH</scp> Special Issue. Journal of Viral Hepatitis, 2014, 21, e167-8.	2.0	2
374	Maternal smoking during pregnancy and offspring smoking initiation: assessing the role of intrauterine exposure. Addiction, 2014, 109, 1013-1021.	3.3	44
375	Commentary on Nolanet al. (2014): Opiate substitution treatment and hepatitis C virus prevention: building an evidence base?. Addiction, 2014, 109, 2060-2061.	3.3	13
376	Outcomes of childhood conduct problem trajectories in early adulthood: findings from the ALSPAC study. European Child and Adolescent Psychiatry, 2014, 23, 539-549.	4.7	69
377	Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness. International Journal of Drug Policy, 2014, 25, 34-52.	3.3	238
378	Investigating local policy drivers for alcohol harm prevention: a comparative case study of two local authorities in England. Lancet, The, 2014, 384, S52.	13.7	1

#	Article	IF	CITATIONS
379	High risk of hepatitis B virus infection and unmet case-finding need among migrants in Bristol, UK: a cross-sectional study. Lancet, The, 2014, 384, S31.	13.7	0
380	Directional Relationships Between Alcohol Use and Antisocial Behavior Across Adolescence. Alcoholism: Clinical and Experimental Research, 2014, 38, 2024-2033.	2.4	16
381	Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ, The, 2014, 349, g5725-g5725.	6.0	115
382	Errors in reported degrees and respondent driven sampling: Implications for bias. Drug and Alcohol Dependence, 2014, 142, 120-126.	3.2	33
383	Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health, 2014, 14, 700.	2.9	178
384	Assessing the costâ€effectiveness of finding cases of hepatitis C infection in <scp>UK</scp> migrant populations and the value of further research. Journal of Viral Hepatitis, 2014, 21, 616-623.	2.0	14
385	Illicit and pharmaceutical drug consumption estimated via wastewater analysis. Part B: Placing back-calculations in a formal statistical framework. Science of the Total Environment, 2014, 487, 642-650.	8.0	48
386	Factors associated with recent symptoms of an injection site infection or injury among people who inject drugs in three English cities. International Journal of Drug Policy, 2014, 25, 303-307.	3.3	26
387	Adolescent Alcohol Use Is Positively Associated With Later Depression in a Population-Based U.K. Cohort. Journal of Studies on Alcohol and Drugs, 2014, 75, 758-765.	1.0	50
388	Case-finding for hepatitis C in primary care: a mixed-methods service evaluation. British Journal of General Practice, 2014, 64, e67-e74.	1.4	14
389	OR09-4 * SCRIPT IN A DAY (SCID) INTERVENTION FOR INDIVIDUALS WHO ARE INJECTING OPIATES: RESULTS FROM A MIXED METHODS FEASIBILITY RANDOMISED CONTROL TRIAL. Alcohol and Alcoholism, 2014, 49, i46-i46.	1.6	0
390	Socioeconomic Status and Alcohol-Related Behaviors in Mid- to Late Adolescence in the Avon Longitudinal Study of Parents and Children. Journal of Studies on Alcohol and Drugs, 2014, 75, 541-545.	1.0	52
391	Establishing the Melbourne injecting drug user cohort study (MIX): rationale, methods, and baseline and twelve-month follow-up results. Harm Reduction Journal, 2013, 10, 11.	3.2	82
392	Adolescent Alcohol Use is Predicted by Childhood Temperament Factors Before Age 5, with Mediation Through Personality and Peers. Alcoholism: Clinical and Experimental Research, 2013, 37, 2108-2117.	2.4	36
393	How costâ€effective is hepatitis C virus treatment for people who inject drugs?. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 590-592.	2.8	10
394	Development of a comparative cost-effectiveness appraisal instrument for local alcohol policies: a modelling study. Lancet, The, 2013, 382, S75.	13.7	0
395	Is the HCV–HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?. Drug and Alcohol Dependence, 2013, 132, 172-181.	3.2	40
396	Inequalities in the uptake of Human Papillomavirus Vaccination: a systematic review and meta-analysis. International Journal of Epidemiology, 2013, 42, 896-908.	1.9	121

#	Article	IF	CITATIONS
397	The relationship between alcohol use and injecting drug use: Impacts on health, crime and wellbeing. Drug and Alcohol Dependence, 2013, 128, 111-115.	3.2	31
398	The health, social and educational needs of children who have survived meningitis and septicaemia: the parents' perspective. BMC Public Health, 2013, 13, 954.	2.9	8
399	Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. International Journal of Drug Policy, 2013, 24, 85-100.	3.3	23
400	Could low dead-space syringes really reduce HIV transmission to low levels?. International Journal of Drug Policy, 2013, 24, 8-14.	3.3	24
401	Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1588-1591.	2.2	26
402	Conduct problem trajectories and alcohol use and misuse in mid to late adolescence. Drug and Alcohol Dependence, 2013, 133, 100-107.	3.2	27
403	Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact. Vaccine, 2013, 31, 2638-2646.	3.8	129
404	Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open, 2013, 3, e003153.	1.9	74
405	Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy. Clinical Infectious Diseases, 2013, 57, S39-S45.	5.8	275
406	A cross-sectional study of emergency department visits by people who inject drugs: Table 1. Emergency Medicine Journal, 2013, 30, 421-422.	1.0	12
407	Mitigating the risk of HIV infection with opioid substitution treatment. Bulletin of the World Health Organization, 2013, 91, 148-149.	3.3	36
408	Mortality among people who inject drugs: a systematic review and meta-analysis. Bulletin of the World Health Organization, 2013, 91, 102-123.	3.3	362
409	Could a peer-led intervention increase uptake of chlamydia screening? A proof of principle pilot study. Journal of Family Planning and Reproductive Health Care, 2013, 39, 21-28.	0.8	6
410	Association of Maternal Smoking With Child Cotinine Levels. Nicotine and Tobacco Research, 2013, 15, 2029-2036.	2.6	14
411	Early life socioâ€economic position and later alcohol use: birth cohort study. Addiction, 2013, 108, 516-525.	3.3	35
412	Early life influences on the risk of injecting drug use: case control study based on the <scp>E</scp> dinburgh <scp>A</scp> ddiction <scp>C</scp> ohort. Addiction, 2013, 108, 743-750.	3.3	18
413	Commentary on de Vos <i>et al</i> . (2013): Can ecological trends in <scp>HIV</scp> or <scp>HCV</scp> incidence be used to assess intervention impact?. Addiction, 2013, 108, 1082-1083.	3.3	2
414	Dimensions of Parental Alcohol Use/Problems and Offspring Temperament, Externalizing Behaviors, and Alcohol Use/Problems. Alcoholism: Clinical and Experimental Research, 2013, 37, 2118-2127.	2.4	43

#	Article	IF	CITATIONS
415	Low incidence of hepatitis C virus among prisoners in <scp>S</scp> cotland. Addiction, 2013, 108, 1296-1304.	3.3	52
416	Multiple parameter evidence synthesis—a potential solution for when information on drug use and harm is in conflict. Addiction, 2013, 108, 1529-1531.	3.3	16
417	Childhood conduct disorder trajectories, prior risk factors and cannabis use at age 16: birth cohort study. Addiction, 2013, 108, 2129-2138.	3.3	52
418	USING MENDELIAN RANDOMISATION TO INFER CAUSALITY IN DEPRESSION AND ANXIETY RESEARCH. Depression and Anxiety, 2013, 30, 1185-1193.	4.1	27
419	Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology, 2013, 58, 1598-1609.	7.3	431
420	Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. Aids, 2013, 27, 2551-2557.	2.2	152
421	Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 Medicine Reports, 2013, 5, 2.	2.9	65
422	Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ, The, 2012, 345, e5945-e5945.	6.0	363
423	The More You Look, the More You Find: Effects of Hepatitis C Virus Testing Interval on Reinfection Incidence and Clearance and Implications for Future Vaccine Study Design. Journal of Infectious Diseases, 2012, 205, 1342-1350.	4.0	64
424	Premature Mortality in Scottish Injecting Drug Users: A Life-history Approach. Scottish Medical Journal, 2012, 57, 38-42.	1.3	8
425	Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. European Journal of Public Health, 2012, 22, 187-192.	0.3	79
426	Patterns of alcohol use and multiple risk behaviour by gender during early and late adolescence: the ALSPAC cohort. Journal of Public Health, 2012, 34, i20-i30.	1.8	129
427	Multiple risk behaviour in adolescence. Journal of Public Health, 2012, 34, i1-i2.	1.8	103
428	Patterns of Alcohol Use in Early Adolescence Predict Problem Use at Age 16. Alcohol and Alcoholism, 2012, 47, 169-177.	1.6	56
429	Investigation of a large community-based outbreak of hepatitis B infection in the United Kingdom. Epidemiology and Infection, 2012, 140, 47-57.	2.1	9
430	Spatial mapping of hepatitis C prevalence in recent injecting drug users in contact with services. Epidemiology and Infection, 2012, 140, 1054-1063.	2.1	7
431	Commentary on <scp>K</scp> elty & <scp>H</scp> ulse (2012): Is the comparison of mortality between patients prescribed implanted or oral naltrexone an unbiased and unconfounded comparison?. Addiction, 2012, 107, 1825-1826.	3.3	2
432	Risk adjustment of heroin treatment outcomes for comparative performance assessment in <scp>E</scp> ngland. Addiction, 2012, 107, 2161-2172.	3.3	27

#	Article	IF	CITATIONS
433	Molecular epidemiology of a large community-based outbreak of hepatitis B in Bristol, UK. Journal of Clinical Virology, 2012, 53, 125-129.	3.1	8
434	Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings—Implications for intervention impact. Drug and Alcohol Dependence, 2012, 123, 122-131.	3.2	34
435	Comparison of Ethyl Glucuronide in Hair with Self-Reported Alcohol Consumption. Alcohol and Alcoholism, 2012, 47, 267-272.	1.6	40
436	Respondent driven sampling and community structure in a population of injecting drug users, Bristol, UK. Drug and Alcohol Dependence, 2012, 126, 324-332.	3.2	19
437	Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Medical Journal of Australia, 2012, 196, 638-641.	1.7	51
438	Commentary on Mehta <i>et al</i> . (2012): Natural history of injecting drug use. Addiction, 2012, 107, 359-360.	3.3	1
439	Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis <scp>C</scp> virus prevalence? Model projections for different epidemic settings. Addiction, 2012, 107, 1984-1995.	3.3	128
440	Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology, 2012, 55, 49-57.	7.3	194
441	Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug and Alcohol Dependence, 2011, 113, 83-85.	3.2	33
442	Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. Journal of Hepatology, 2011, 54, 1137-1144.	3.7	199
443	Optimal Control of Hepatitis C Antiviral Treatment Programme Delivery for Prevention amongst a Population of Injecting Drug Users. PLoS ONE, 2011, 6, e22309.	2.5	36
444	Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction, 2011, 106, 32-51.	3.3	669
445	The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction, 2011, 106, 1978-1988.	3.3	271
446	Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. Journal of Viral Hepatitis, 2011, 18, 262-270.	2.0	81
447	Testing a Level of Response to Alcohol-Based Model of Heavy Drinking and Alcohol Problems in 1,905 17-year-olds. Alcoholism: Clinical and Experimental Research, 2011, 35, 1897-1904.	2.4	27
448	Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6793-6799.	2.2	31
449	Mathematical modelling of hepatitis C treatment for injecting drug users. Journal of Theoretical Biology, 2011, 274, 58-66.	1.7	86
450	Patients receiving opiate substitution have elevated mortality risks at the start and end of treatment. Evidence-Based Mental Health, 2011, 14, 39-39.	4.5	0

#	Article	IF	CITATIONS
451	Characterizing Patterns of Smoking Initiation in Adolescence: Comparison of Methods for Dealing With Missing Data. Nicotine and Tobacco Research, 2011, 13, 1266-1275.	2.6	24
452	A systematic review of interventions to increase the uptake of opiate substitution therapy in injecting drug users. Journal of Public Health, 2011, 33, 378-384.	1.8	6
453	Adolescent Alcohol and Tobacco Use and Early Socioeconomic Position: The ALSPAC Birth Cohort. Pediatrics, 2011, 127, e948-e955.	2.1	139
454	Promoting recovery and preventing drug-related mortality: competing risks?. Journal of Public Health, 2011, 33, 332-334.	1.8	13
455	The Edinburgh Addiction Cohort: recruitment and follow-up of a primary care based sample of injection drug users and non drug-injecting controls. BMC Public Health, 2010, 10, 101.	2.9	9
456	Can hepatitis C virus prevalence be used as a measure of injectionâ€related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction, 2010, 105, 311-318.	3.3	77
457	How ideology shapes the evidence and the policy: what do we know about cannabis use and what should we do?. Addiction, 2010, 105, 1326-1330.	3.3	29
458	Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction, 2010, 105, 844-859.	3.3	209
459	RESPONSE TO COMMENTARIES: MOVING TOWARDS AN EVIDENCEâ€BASED POLICY AROUND CANNABIS USE. Addiction, 2010, 105, 1337-1339.	3.3	1
460	Recording of clinical information in a Scotland-wide drug deaths study. Journal of Psychopharmacology, 2010, 24, 1289-1298.	4.0	3
461	Characteristics of injecting drug users accessing different types of needle and syringe programme or using secondary distribution. Journal of Public Health, 2010, 32, 328-335.	1.8	21
462	Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ: British Medical Journal, 2010, 341, c3172-c3172.	2.3	168
463	Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. BMJ: British Medical Journal, 2010, 341, c4851-c4851.	2.3	114
464	Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ: British Medical Journal, 2010, 341, c5475-c5475.	2.3	250
465	Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2010, 10, 853-861.	9.1	514
466	HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet, The, 2010, 375, 1014-1028.	13.7	629
467	Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet, The, 2010, 376, 285-301.	13.7	382
468	Policy resistance to harm reduction for drug users and potential effect of change. BMJ: British Medical Journal, 2010, 341, c3439-c3439.	2.3	37

#	Article	IF	CITATIONS
469	Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiology and Infection, 2009, 137, 1255-1265.	2.1	71
470	Estimating the prevalence of ex-injecting drug use in the population. Statistical Methods in Medical Research, 2009, 18, 381-395.	1.5	56
471	An evidence synthesis approach to estimating Hepatitis C Prevalence in England and Wales. Statistical Methods in Medical Research, 2009, 18, 361-379.	1.5	65
472	Measuring risk of HIV and HCV among injecting drug users in the Russian Federation. European Journal of Public Health, 2009, 19, 428-433.	0.3	12
473	Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. Journal of Public Health, 2009, 31, 374-382.	1.8	44
474	Hepatitis C Infection Among Injecting Drug Users in England and Wales (1992-2006): There and Back Again?. American Journal of Epidemiology, 2009, 170, 352-360.	3.4	50
475	If cannabis caused schizophrenia—how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. Addiction, 2009, 104, 1856-1861.	3.3	51
476	ls socioeconomic status in early life associated with drug use? A systematic review of the evidence. Drug and Alcohol Review, 2009, 28, 142-153.	2.1	110
477	Frequency, factors and costs associated with injection site infections: Findings from a national multi-site survey of injecting drug users in England. BMC Infectious Diseases, 2008, 8, 120.	2.9	97
478	Trends in overdose deaths from drug misuse in Europe: what do the data tell us?. Addiction, 2008, 103, 699-700.	3.3	19
479	Does alcohol increase the risk of overdose death: the need for a translational approach. Addiction, 2008, 103, 1060-1062.	3.3	67
480	UNDERSTANDING CAUSAL PATHWAYS: A RESPONSE TO THE COMMENTARIES. Addiction, 2008, 103, 1067-1068.	3.3	2
481	Estimating the size and dynamics of an injecting drug user population and implications for health service coverage: comparison of indirect prevalence estimation methods. Addiction, 2008, 103, 1604-1613.	3.3	27
482	Parental drug use, early adversities, later childhood problems and children's use of tobacco and alcohol at age 10: birth cohort study. Addiction, 2008, 103, 1731-1743.	3.3	55
483	Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. Journal of Viral Hepatitis, 2008, 15, 250-254.	2.0	102
484	Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet, The, 2008, 372, 1733-1745.	13.7	1,107
485	Estimating hepatitis C prevalence in England and Wales by synthesizing evidence from multiple data sources. Assessing data conflict and model fit. Biostatistics, 2008, 9, 715-734.	1.5	38
486	Intrauterine Exposure to Alcohol and Tobacco Use and Childhood IQ: Findings from a Parental-Offspring Comparison within the Avon Longitudinal Study of Parents and Children. Pediatric Research, 2008, 64, 659-666.	2.3	74

#	Article	IF	CITATIONS
487	Changes in HIV Prevalence and Risk Among New Injecting Drug Users in a Russian City of High HIV Prevalence. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 623-631.	2.1	19
488	Differences between injectors and non-injectors, and a high prevalence of benzodiazepines among drug related deaths in Scotland 2003. Addiction Research and Theory, 2007, 15, 651-662.	1.9	4
489	Comparing population estimates for drug users, the prevalence of blood-borne viruses and the provision of services in one London borough: Evidence of a gap in provision?. Drugs: Education, Prevention and Policy, 2007, 14, 205-215.	1.3	0
490	Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. International Journal of Epidemiology, 2007, 36, 396-405.	1.9	79
491	Cannabis and psychosis. Lancet, The, 2007, 370, 1539.	13.7	13
492	Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales?. Journal of Viral Hepatitis, 2007, 14, 584-591.	2.0	21
493	Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. Journal of Viral Hepatitis, 2007, 14, 645-652.	2.0	86
494	Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: is the prison vaccination programme driving recent improvements?. Journal of Viral Hepatitis, 2007, 14, 653-660.	2.0	22
495	London audit of drug-related overdose deaths: characteristics and typology, and implications for prevention and monitoring. Addiction, 2007, 102, 317-323.	3.3	56
496	Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction, 2007, 102, 597-606.	3.3	79
497	Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia. Addiction, 2007, 102, 1244-1250.	3.3	48
498	Socioâ€economic status in childhood and later alcohol use: a systematic review*. Addiction, 2007, 102, 1546-1563.	3.3	69
499	Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multiâ€site prospective cohort study. Addiction, 2007, 102, 1954-1959.	3.3	190
500	Validating estimates of problematic drug use in England. BMC Public Health, 2007, 7, 286.	2.9	5
501	RESPONSE TO THE COMMENTARIES. Addiction, 2007, 102, 516-518.	3.3	2
502	Does cannabis use cause schizophrenia?. Lancet, The, 2006, 367, 1055.	13.7	23
503	Harm-reduction interventions in injection drug use. Lancet, The, 2006, 367, 1797-1798.	13.7	1
504	Estimating prevalence of injecting drug use: a comparison of multiplier and capture-recapture methods in cities in England and Russia. Drug and Alcohol Review, 2006, 25, 131-140.	2.1	34

#	Article	IF	CITATIONS
505	Model Projections on the Required Coverage of Syringe Distribution to Prevent HIV Epidemics Among Injecting Drug Users. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 355-361.	2.1	64
506	Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infectious Diseases, 2006, 6, 93.	2.9	70
507	Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multiâ€eity study. Addiction, 2006, 101, 252-266.	3.3	103
508	Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the â€~Treating 3 million by 2005. Making it happen. The WHO strategy' (â€~3by5'). Addiction, 2006, 101, 1246-1253.	3.3	61
509	Public injecting and the need for â€~safer environment interventions' in the reduction of drug-related harm. Addiction, 2006, 101, 1384-1393.	3.3	195
510	Methods to Recruit Hard-to-Reach Groups: Comparing Two Chain Referral Sampling Methods of Recruiting Injecting Drug Users Across Nine Studies in Russia and Estonia. Journal of Urban Health, 2006, 83, i39-53.	3.6	106
511	Drug-related mortality and its impact on adult mortality in eight European countries. European Journal of Public Health, 2006, 16, 198-202.	0.3	142
512	Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993–2004. International Journal of Epidemiology, 2006, 35, 1579-1585.	1.9	45
513	Commentary: Understanding pathways to cannabis use and from use to harm. International Journal of Epidemiology, 2006, 35, 680-682.	1.9	9
514	Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sexually Transmitted Infections, 2006, 82, iii10-iii17.	1.9	110
515	Prevalence of problematic and injecting drug use for Drug Action Team areas in England. Journal of Public Health, 2006, 28, 3-9.	1.8	14
516	Trends in deaths related to drug misuse in England and Wales, 1993-2004. Health Statistics Quarterly, 2006, , 23-7.	0.9	6
517	Indirect Methods to Estimate Prevalence. , 2005, , 113-131.		19
518	HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. Aids, 2005, 19, 1207-1214.	2.2	41
519	Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. Journal of Viral Hepatitis, 2005, 12, 655-662.	2.0	55
520	REPORTING BIAS AND SELF-REPORTED DRUG USE. Addiction, 2005, 100, 562-563.	3.3	36
521	Capturing crack cocaine use: estimating the prevalence of crack cocaine use in London using capture-recapture with covariates. Addiction, 2005, 100, 1701-1708.	3.3	55
522	Methods for assessing HIV and HIV risk among IDUs and for evaluating interventions. International Journal of Drug Policy, 2005, 16, 7-20.	3.3	9

#	Article	IF	CITATIONS
523	Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia. International Journal of STD and AIDS, 2005, 16, 749-754.	1.1	36
524	Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ: British Medical Journal, 2005, 330, 24-25.	2.3	145
525	Hospital admissions for drug and alcohol use in people aged under 45. BMJ: British Medical Journal, 2005, 330, 115.	2.3	19
526	â€~Trapping' in drug use and sex work careers. Drugs: Education, Prevention and Policy, 2005, 12, 369-379.	1.3	41
527	Continuing the epidemiological function of the addicts index—evidence from matching the home office addicts index with the National Drug Treatment Monitoring System. Drugs: Education, Prevention and Policy, 2004, 11, 91-100.	1.3	2
528	Injecting drug use in Brighton, Liverpool, and London: best estimates of prevalence and coverage of public health indicators. Journal of Epidemiology and Community Health, 2004, 58, 766-771.	3.7	86
529	Estimating Long-term Trends in the Incidence and Prevalence of Opiate Use/Injecting Drug Use and the Number of Former Users: Back-Calculation Methods and Opiate Overdose Deaths. American Journal of Epidemiology, 2004, 160, 994-1004.	3.4	70
530	Effectiveness of preventing frequent cannabis use among young people in improving educational achievement: eradicating frequent cannabis use among adolescents could reduce school dropout by 3%. Addiction, 2004, 99, 650-651.	3.3	3
531	The prevalence of injecting drug use in a Russian city: implications for harm reduction and coverage. Addiction, 2004, 99, 1430-1438.	3.3	31
532	How strong is the evidence that illicit drug use by young people is an important cause of psychological or social harm? methodological and policy implications of a systematic review of longitudinal, general population studies. Drugs: Education, Prevention and Policy, 2004, 11, 281-297.	1.3	13
533	Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet, The, 2004, 363, 1579-1588.	13.7	577
534	Clobal overview of injecting drug use and HIV infection among injecting drug users. Aids, 2004, 18, 2295-2303.	2.2	392
535	Drug-Related Mortality and Fatal Overdose Risk: Pilot Cohort Study of Heroin Users Recruited From Specialist Drug Treatment Sites in London. Journal of Urban Health, 2003, 80, 274-287.	3.6	87
536	Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. Journal of Medical Virology, 2003, 71, 49-55.	5.0	152
537	Trends in drug overdose deaths in England and Wales 1993-98: methadone does not kill more people than heroin. Addiction, 2003, 98, 419-425.	3.3	62
538	Early Exposure to Marijuana and Risk of Later Drug UseEarly Exposure to Marijuana and Risk of Later Drug Use. JAMA - Journal of the American Medical Association, 2003, 290, 329.	7.4	1
539	Responding to Drug Use in Jersey: findings and outcomes from a multimethod rapid assessment. Drugs: Education, Prevention and Policy, 2003, 10, 223-234.	1.3	4
540	Arrest Referral in London Police Stations: characteristics of the first year. A key point of intervention for drug users?. Drugs: Education, Prevention and Policy, 2003, 10, 73-85.	1.3	13

#	Article	IF	CITATIONS
541	Early Exposure to Marijuana and Risk of Later Drug Use. JAMA - Journal of the American Medical Association, 2003, 290, 329-b-330.	7.4	3
542	Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. Aids, 2002, 16, F25-F31.	2.2	126
543	Heavy users of acute psychiatric beds: randomized controlled trial of enhanced community management in an outer London borough. Psychological Medicine, 2002, 32, 403-416.	4.5	72
544	Over a decade of syringe exchange: results from 1997 UK survey. Addiction, 2002, 97, 845-850.	3.3	30
545	Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working?. American Journal of Public Health, 2001, 91, 38-42.	2.7	68
546	A comparison of different methods for estimating the prevalence of problematic drug misuse in Great Britain. Addiction, 2001, 96, 1465-1476.	3.3	71
547	The prevalence and management of coâ€morbid substance misuse and mental illness: results of a screening survey in substance misuse and mental health treatment populations. Drug and Alcohol Review, 2001, 20, 407-416.	2.1	17
548	Estimating the Relative Incidence of Heroin Use: Application of a Method for Adjusting Observed Reports of First Visits to Specialized Drug Treatment Agencies. American Journal of Epidemiology, 2001, 153, 632-641.	3.4	27
549	Costs and Characteristics of Heavy Inpatient Service Users in Outer London. International Journal of Social Psychiatry, 2001, 47, 63-74.	3.1	73
550	Measuring injecting risk behaviour in the second decade of harm reduction: a survey of injecting drug users in England. Addiction, 2000, 95, 1351-1361.	3.3	44
551	A comparison of trends in problematic drug misuse from two reporting systems. Journal of Public Health, 2000, 22, 362-367.	1.8	8
552	Prevalence of HIV infection in a multi-site sample of injecting drug users not in contact with treatment services in England. Aids, 2000, 14, 2413-2415.	2.2	8
553	Accuracy of perceptions of hepatitis B and C status. BMJ: British Medical Journal, 2000, 320, 512-512.	2.3	2
554	Impact of HIV on adult (15-54) mortality in London: 1979-96. Sexually Transmitted Infections, 1999, 75, 385-388.	1.9	9
555	Outcomes of universal antenatal screening for haemoglobinopathies. Journal of Medical Screening, 1999, 6, 3-10.	2.3	35
556	Surveillance of problem drug use in the UK: a review of a Regional Drug Misuse Database. Journal of Public Health, 1999, 21, 271-277.	1.8	11
557	Incidence of gonorrhoea diagnosed in GUM clinics in South Thames (west) region. Sexually Transmitted Infections, 1999, 75, 306-311.	1.9	17
558	Estimating the prevalence of problem drug use in inner London: a discussion of three captureâ€recapture studies. Addiction, 1999, 94, 1653-1662.	3.3	54

#	Article	IF	CITATIONS
559	Mapping the prevalence of sickle cell and beta thalassaemia in England: estimating and validating ethnicâ€specific rates. British Journal of Haematology, 1999, 104, 860-867.	2.5	101
560	HIV prevalence and risk behaviour among female injecting drug users in London, 1990 to 1996. Aids, 1999, 13, 833-837.	2.2	10
561	Assessment of the Feasibility of Conducting Population Prevalence Studies of Chronic Renal Failure According to Ethnic Group: A Survey of Clinical Biochemistry Laboratories in Greater London and South East England. Annals of Clinical Biochemistry, 1999, 36, 94-98.	1.6	1
562	Surveillance of sexually transmitted infections: fit for purpose?. International Journal of STD and AIDS, 1999, 10, 493-494.	1.1	7
563	Costing model for neonatal screening and diagnosis of haemoglobinopathies. Archives of Disease in Childhood: Fetal and Neonatal Edition, 1998, 79, F161-F167.	2.8	23
564	Statistics on misuse of drugs have been misused. BMJ: British Medical Journal, 1998, 317, 1388-1388.	2.3	3
565	Validation of a regional drug misuse database: implications for policy and surveillance of problem drug use in the uk. BMJ: British Medical Journal, 1997, 315, 581-581.	2.3	13
566	Geographic variation in sexual behaviour in Britain: implications for sexually transmitted disease epidemiology and sexual health promotion. Aids, 1996, 10, 193-199.	2.2	21
567	Neonatal screening. BMJ: British Medical Journal, 1996, 312, 182-182.	2.3	5
568	A taxonomy of shared care for chronic disease. Journal of Public Health, 1994, 16, 447-454.	1.8	87
569	AIDS surveillance: a direct assessment of under-reporting. Aids, 1993, 7, 1661-1665.	2.2	6
570	HIV seroprevalence in a defined London population. Lancet, The, 1990, 336, 1328-1329.	13.7	1
571	DONOR SCREENING FOR HIV: HOW MANY FALSE NEGATIVES?. Lancet, The, 1988, 331, 1221.	13.7	8
572	Individual-, family-, and school-level interventions targeting multiple-risk behaviours in young people. The Cochrane Library, 0, , .	2.8	10
573	Individual-, family-, and school-level interventions for preventing multiple risk behaviours relating to alcohol, tobacco and drug use in individuals aged 8 to 25 years. The Cochrane Library, 0, , .	2.8	9
574	Effectiveness of psychosocial interventions for reducing parental substance misuse. The Cochrane Library, 0, , .	2.8	6
575	A Neurocognitive Investigation of Low-Level Arsenic Exposure Reveals Impaired Executive Function Mediated by Brain Anomalies. SSRN Electronic Journal, 0, , .	0.4	0
576	Refining the content and design of an alcohol reduction app, Drink Less, to improve its usability and effectiveness: a mixed methods approach. F1000Research, 0, 10, 511.	1.6	8